Company registration number 02407019 (England and Wales)
RAYTEK SCIENTIFIC LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
PAGES FOR FILING WITH REGISTRAR
RAYTEK SCIENTIFIC LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 5
RAYTEK SCIENTIFIC LIMITED
BALANCE SHEET
AS AT
31 AUGUST 2025
31 August 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
354
320
Current assets
Stocks
16,147
16,823
Debtors
4
180,233
211,263
Cash at bank and in hand
80
49
196,460
228,135
Creditors: amounts falling due within one year
5
(11,785)
(22,314)
Net current assets
184,675
205,821
Total assets less current liabilities
185,029
206,141
Creditors: amounts falling due after more than one year
6
-
0
(1,393)
Net assets
185,029
204,748
Capital and reserves
Called up share capital
51
51
Capital redemption reserve
49
49
Profit and loss reserves
184,929
204,648
Total equity
185,029
204,748
RAYTEK SCIENTIFIC LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 AUGUST 2025
31 August 2025
- 2 -

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 11 May 2026
A Dewar
Director
Company registration number 02407019 (England and Wales)
RAYTEK SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
- 3 -
1
Accounting policies
Company information

Raytek Scientific Limited is a private company limited by shares incorporated in England and Wales. The registered office is First Floor, Unit 4 Broadfield Court, Sheffield, South Yorkshire, S8 0XF.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Revenue

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

 

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
25% on cost
1.5
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

RAYTEK SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.7
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
1
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 September 2024
18,776
Additions
239
At 31 August 2025
19,015
Depreciation and impairment
At 1 September 2024
18,456
Depreciation charged in the year
205
At 31 August 2025
18,661
Carrying amount
At 31 August 2025
354
At 31 August 2024
320
RAYTEK SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 5 -
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
5,816
3,262
Other debtors
174,417
208,001
180,233
211,263
5
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
1,393
1,638
Trade creditors
-
0
141
Corporation tax
969
11,747
Other taxation and social security
7,149
6,513
Other creditors
2,274
2,275
11,785
22,314
6
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
-
0
1,393
7
Directors' transactions

Advances or credits have been granted by the company to its directors as follows:

Dividends totalling £23,820 (2024 - £35,300) were paid in the year in respect of shares held by the company's directors.

Interest is payable on the loans subsisting during the year. Interest is calculated at HMRC beneficial loan interest rates, which was 2.25% until 5th April 2025 and 3.75% from 6th April 2025 All amounts are unsecured and repayable on demand.

Advances
Opening balance
Amounts advanced
Amounts repaid
Closing balance
£
£
£
£
Directors Loan
166,128
14,885
(51,028)
129,985
166,128
14,885
(51,028)
129,985
2025-08-312024-09-01falsefalsefalse20 May 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityA DewarA Dewar024070192024-09-012025-08-31024070192025-08-31024070192024-08-3102407019core:OtherPropertyPlantEquipment2025-08-3102407019core:OtherPropertyPlantEquipment2024-08-3102407019core:CurrentFinancialInstrumentscore:WithinOneYear2025-08-3102407019core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3102407019core:Non-currentFinancialInstrumentscore:AfterOneYear2025-08-3102407019core:Non-currentFinancialInstrumentscore:AfterOneYear2024-08-3102407019core:CurrentFinancialInstruments2025-08-3102407019core:CurrentFinancialInstruments2024-08-3102407019core:ShareCapital2025-08-3102407019core:ShareCapital2024-08-3102407019core:CapitalRedemptionReserve2025-08-3102407019core:CapitalRedemptionReserve2024-08-3102407019core:RetainedEarningsAccumulatedLosses2025-08-3102407019core:RetainedEarningsAccumulatedLosses2024-08-3102407019bus:CompanySecretaryDirector12024-09-012025-08-3102407019core:PlantMachinery2024-09-012025-08-31024070192023-09-012024-08-3102407019core:OtherPropertyPlantEquipment2024-08-3102407019core:OtherPropertyPlantEquipment2024-09-012025-08-3102407019core:Non-currentFinancialInstruments2025-08-3102407019core:Non-currentFinancialInstruments2024-08-3102407019bus:PrivateLimitedCompanyLtd2024-09-012025-08-3102407019bus:SmallCompaniesRegimeForAccounts2024-09-012025-08-3102407019bus:FRS1022024-09-012025-08-3102407019bus:AuditExemptWithAccountantsReport2024-09-012025-08-3102407019bus:Director12024-09-012025-08-3102407019bus:CompanySecretary12024-09-012025-08-3102407019bus:FullAccounts2024-09-012025-08-31xbrli:purexbrli:sharesiso4217:GBP